Structured evidence table for Calcium Citrate Absorption Randomized Trial, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Calcium Citrate Absorption Randomized Trial | A variable degree of carbonation can be seen in stones, and greater carbonate content is associated with culturable microorganisms on the crystal surface, raising the potential need to evaluate for urinary tract infection.Not all laboratories report the presence of carbonated hydroxyapatite or quantify the degree of carbonation. | 3 | Tsai Peihsuan (2026) | Calcium Phosphate Nephrolithiasis: A Comprehensive Review |
| Calcium Citrate Absorption Randomized Trial | Cohort studies have identified 3 main urinary risk factors associated with CaP stone formation: high urine pH, hypercalciuria, and hypocitraturia(). | 3 | Tsai Peihsuan (2026) | Calcium Phosphate Nephrolithiasis: A Comprehensive Review |
| Calcium Citrate Absorption Randomized Trial | We will next review these clinical risk factors individually and review insights from histopathologic evidence. | 3 | Tsai Peihsuan (2026) | Calcium Phosphate Nephrolithiasis: A Comprehensive Review |
| Calcium Citrate Absorption Randomized Trial | Calcium phosphate (CaP) kidney stones are the second most encountered stone type. | 3 | Tsai Peihsuan (2026) | Calcium Phosphate Nephrolithiasis: A Comprehensive Review |
| Calcium Citrate Absorption Randomized Trial | Reduced kidney function in these patients leads to a range of pathological changes in mineral metabolism termed mineral and bone disorder (MBD)[]. | 4 | Ilkun Olesya (2026) | Emerging treatments and current strategies for mineral, vascular, and bone disorders in chronic kidney disease |
| Calcium Citrate Absorption Randomized Trial | Indeed, high serum phosphate in patients with ESKD is associated with increased risk of all-cause[,] and cardiovascular (CV) mortality[,], as well as bone fractures[]. | 4 | Ilkun Olesya (2026) | Emerging treatments and current strategies for mineral, vascular, and bone disorders in chronic kidney disease |
| Calcium Citrate Absorption Randomized Trial | Elevated calcium levels are also associated with increased mortality across all stages of kidney disease, but particularly so in ESKD[,]. | 4 | Ilkun Olesya (2026) | Emerging treatments and current strategies for mineral, vascular, and bone disorders in chronic kidney disease |
| Calcium Citrate Absorption Randomized Trial | Patients with advanced chronic kidney disease and end-stage kidney disease experience disproportionally high morbidity and mortality compared to the general population, particularly from cardiovascular disease and following bone fractures. | 4 | Ilkun Olesya (2026) | Emerging treatments and current strategies for mineral, vascular, and bone disorders in chronic kidney disease |
Source documents